8.1.2 Performance Status Assessment 
See Appendix 12.2 for Kamofsky Performance Status assessment. 
8.1.3 Pre-treatment Laboratory 
CBC with differential, platelet count, PT, PTT, glucose, BUN, creatinine, electrolytes, SCOT, SGPT, 
LDH, alkaline phosphatase, bilirubin, uric acid, calcium, total protein and albumin. 
Urinalysis 
CH50, C3 and C4 serum complement levels 
Immunophenotyping of peripheral blood B cell and T cell subsets (if sufficient cells are available) 
PCR of peripheral blood leukocytes for neo^ and viral env 
Serum IL-2 concentration 
Humoral tumor immunity - serum anti-tumor titers 
Cellular tumor immunity - Cytotoxic T cell assays against autologous tumor cells. Delayed type- 
hypersensitivity (DTH) skin testing will be performed at the discretion of the investigators and depending 
upon the availability of tumor cells. Aliquots of 10^ autologous tumor cells will be utilized for DTH skin 
testing. The cells will be drawn up in 0.2 ml of normal saline and injected intradermally. Induration will 
be measured at 24 and 28 hours. A medium ball point pen will be placed at 45° angle to the patient's 
skin, and the injection site approached from each of 4 sides until resistance is encountered. The area thus 
circumscribed will be measured in 2 diameters with a caliper. Selected DTH sites may be biopsied for 
histological and immunohistochemical analyses to identify the nature of infiltrating immune effector cell 
populations. 
8.1.4 Other Pretreatment Evaluations 
Chest X-ray and other diagnostic studies including computerized tomography (CT), magnetic resonance 
imaging (MRI) or radionuclide scans will be performed to document and quantitate the extent of disease 
activity. 
8.2 Follow-up Procedures 
After each immunization, patients will be contacted daily for 3 days to determine if the injection site is 
swollen or red. If a history of any erythema or induration is elicited, then the patient will be examined 
within 24 hours. Otherwise, subjects will be examined one week after the first immunization, then at 
approximately 1 to 2 week intervals. At each visit, the patients will be advised to return to the hospital 
and to contact one of the study investigators should they develop inflammation at injection sites or 
experience fever, rash, arthralgias, edema or dyspnea. 
At each visit, the pertinent medical history will be obtained and a physical examination will be performed. 
Laboratory tests described in Section 8.1 will be performed at the weekly and monthly visits. 
Diagnostic studies including X-rays, CT, MRI or radionuclide scans will be performed to evaluate 
responses to therapy. 
Recombinant DNA Research, Volume 19 
[629] 
